COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
Overcoming Ovarian Cancer Chemoresistance - 1st Edition - ISBN: 9780128198407, 9780128198414

Overcoming Ovarian Cancer Chemoresistance, Volume 11

1st Edition

Editors: Goli Samimi Christina Annunziata
Hardcover ISBN: 9780128198407
eBook ISBN: 9780128198414
Imprint: Academic Press
Published Date: 6th November 2020
Page Count: 188
Sales tax will be calculated at check-out Price includes VAT/GST
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

  1. Ovarian Cancer Introduction
    2. Ovarian Cancer Treatment
    3. Chemoresistance in Ovarian Cancer
    4. Circulating DNA as a Monitor of Response
    5. BRCA Mutations and Reversions (e.g. rapid autopsy)
    6. Ovarian Cancer Stem Cells
    7. Immunotherapy/Vaccines
    8. Models of Ovarian Cancer to Test New Agents
    9. Promising Agents on the Horizons


Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment.

The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future.

This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer.

Key Features

  • Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response
  • Discusses genetic reversions as a unique alteration and a new field of study
  • Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field


Cancer researchers, medical scientists, clinicians, graduate students


No. of pages:
© Academic Press 2020
6th November 2020
Academic Press
Hardcover ISBN:
eBook ISBN:

Ratings and Reviews

About the Editors

Goli Samimi

Dr Samimi currently serves as a Program Director in the Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, NCI. She manages the Ovarian Cancer Prevention portfolio and scientific monitoring of early phase ovarian cancer clinical trials within the NCI Division of Cancer Prevention Early Phase Prevention Consortia. Dr. Samimi’s research interests include molecular mechanisms of ovarian cancer etiology, circulating/shed DNA as a biomarker of ovarian cancer, and improving identification of high-risk individuals including BRCA1/2 mutation carriers. Dr. Samimi currently serves on the Trans-NCI Cancer and Bioethics Working Group, and the NCI Moonshot Generation of Human Tumor Atlases Implementation Team.

Affiliations and Expertise

Program Director, The Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, NCI

Christina Annunziata

Dr Annunziata is Principal Investigator and Clinical Director of the Women’s Malignancies Branch at the National Cancer Institute in Bethesda, Maryland. She received her MD and PhD from Georgetown University, and completed residency in Internal Medicine at that institution, followed by Medical Oncology Fellowship at the NCI. In the Intramural Program of the NCI, she runs a translational research laboratory and is involved with several clinical protocols. She has mentored both scientific and clinical fellows, who moved on to Assistant Professor positions, with independent grant funding. Outside the NIH, Dr. Annunziata has chaired grant review committees for ASCO and DOD.

Affiliations and Expertise

Investigator, Women’s Malignancies Branch, Center for Cancer Research, NCI, USA